News and Trends 1 Aug 2022 Arecor Therapeutics adds diabetes product to portfolio after significant acquisition Arecor Therapeutics plc has bought all of Tetris Pharma Ltd shares adding a key commercial diabetes product to its portfolio. The company says as well as expanding its portfolio, the acquisition of the entire issued share capital complements its existing hospital products franchise and will speed up its revenue growth. Injectable products Tetris Pharma has […] August 1, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2022 Treatments set to improve for lethal lung disease and ulcers following drug synergy data revelation New data has been published today (July 7) evidencing findings that could lead to better treatment for people with lethal lung infections and infected diabetic foot ulcers caused by antimicrobial resistant (AMR) bacteria. Clinical stage biotechnology company, Destiny Pharma plc., focused on the development of novel products to prevent life-threatening infections, revealed the publication of […] July 7, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2022 Type 1 diabetes in the crosshairs with Imagine Pharma discovery U.S. biotech company Imagine Pharma is showcasing its discovery of Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) at the American Transplant Congress in Boston. The company said its industry breakthrough is a critical component for the potential treatment of T1D through autologous cell transplantation. T1D AIPCs are novel cell populations generated and propagated […] June 6, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 May 2022 Up to 500 new jobs as Lilly invests $2.1B in new manufacturing sites Eli Lilly and Company is boosting its manufacturing footprint by investing $2.1 billion in two new U.S. sites. The new facilities are located at Indiana’s LEAP Lebanon Innovation and Research District in Boone County. David A. Ricks, Lilly’s chair and CEO, said: “These new sites will add capacity in support of our growing pipeline of […] May 27, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 May 2022 Zealand Pharma’s drug for rare metabolic disease smashes phase III After a year of slumping stock prices, Zealand Pharma is striking back, as its peptide drug improved blood sugar control in infants with the rare disease congenital hyperinsulinemia in a phase III trial. In late 2020, the Danish firm Zealand Pharma A/S hit a big obstacle when its peptide drug dasiglucagon failed to treat the […] May 20, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2022 Evotec, Sernova in partnership to develop beta cell diabetes therapy Evotec and Sernova are set to join forces to advance a beta cell replacement therapy to treat insulin-dependent diabetes. As part of the deal, Evotec will make a €20M equity investment in Sernova. Germany-based Evotec and Canada’s Sernova have agreed on a partnership to develop and commercialize an implantable diabetes therapy based on beta cell […] May 19, 2022 - 3 minutesmins - By Susannah Rodgers Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jul 2021 Poxel’s Diabetes Drug Wins Japan Nod, But Competition Remains Fierce As French biotech Poxel marks the first market approval of its oral type 2 diabetes medication in Japan, eyes turn to the future of this drug and its rivals in Europe and the US. The fortunes of the Lyon-based Poxel have been boosted by the first-ever regulatory approval of its oral type 2 diabetes medication […] July 2, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2021 Farxiga’s Approval Fuels Chronic Kidney Disease Comeback Until this year, there were no effective treatments for chronic kidney disease. However, the recent approval of AstraZeneca’s Farxiga alongside clinical breakthroughs and advances in precision medicine are causing the field to resurge. The last several months have seen big pharma companies scoring wins against chronic kidney disease (CKD). This condition involves gradual, irreversible kidney […] June 8, 2021 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2020 Record Series A for Italian Biotech Funds Autoimmune Therapy Italian biotech Enthera raised €28M in Series A funding to develop its drug candidate for type 1 diabetes and inflammatory bowel disease and take it to human trials. Enthera was founded in 2016 and is the first company to ‘graduate’ from the BiovelocITA accelerator program in Milan, which is supported by French life science investor […] July 28, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 3 Mar 2020 How Immunotherapy Could Stop and Prevent Type 1 Diabetes People with type 1 diabetes need lifelong treatments of daily insulin injections to manage their condition that still leave them at risk of long-term complications. Immunotherapy could one day become an insulin-free alternative to stop, prevent, and potentially cure this chronic disease. Type 1 diabetes is an autoimmune disease where the insulin-producing beta cells in […] March 3, 2020 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 7 Feb 2020 Sigrid Therapeutics Prevents Type 2 Diabetes Using Silica Powder in the Gut In Stockholm, Sweden, Sigrid Therapeutics is developing an ingestible silica powder that can treat type 2 diabetes and obesity without being absorbed in the gut. Mission: To produce the first prophylactic silica-based treatment for type 2 diabetes that does not enter the bloodstream. Some people have higher blood sugar levels than normal, but not high […] February 7, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Feb 2020 Valbiotis Teams up with Nestlé to Reduce Type 2 Diabetes Risk In a deal worth up to €67M, industry giant Nestlé Health Science will have the global rights to commercialize Valbiotis’ food supplement for lowering the rate of type 2 diabetes in people at high risk of developing the condition. Under the terms of the deal, the French biotech will receive an upfront payment of €4.7M […] February 6, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email